Co-founder Mihai Netea (left) in consultation with one of his researchers at Radboudumc’s lab. Photo: Bart van Overbeeke
Biotrip is an incubator that wants to deliver the vaccines and immunotherapies of the future
Eindhoven University of Technology (TU/e) and Radboud University Medical Center (Radboudumc) are co-founding the independent incubator Biotrip. This is a platform that brings together medical scientists and biomedical engineers to work with entrepreneurs to develop, commercialize and deliver vaccines and immunotherapies to patients with a wide range of diseases.
Biotrip is an initiative between two well-known Dutch academic institutions. “If anything, the COVID-19 pandemic has shown the critical importance of biomedical engineering and its merger with clinical research and medicine. Biotrip will yield technologies and commercial opportunities that will help solve the medical challenges of the future”, says TU/e Rector Frank Baaijens. For example, Biotrip aims to develop a novel generation of vaccines to bolster broad protection in the population against emerging SARS-CoV-2 variants and potential future pandemics.
Click the button below to read the entire article via TU/e.